Variations in the cannabinoid receptor 1 gene predispose to migraine

Variations in the cannabinoid receptor 1 gene predispose to migraine

In animal models endogenous cannabinoids have an inhibitory effect on trigeminovascular activation through the cannabinoid receptor 1 (CB1), although there is no evidence of the potential role of CB1 in human migraine. In this study we applied single marker association and haplotypic trend regression analysis to investigate the relationship between the CB1 gene (CNR1) and headache with migraine symptoms (nausea, photophobia and disability, measured by the ID-migraine questionnaire).

Read more
Add your reaction Share

The endocannabinoid system and migraine

The endocannabinoid system and migraine

The recently discovered endocannabinoid system (ECS), which includes endocannabinoids and the proteins that metabolize and bind them, has been implicated in multiple regulatory functions both in health and disease. Several studies have suggested that ECS is centrally and peripherally involved in the processing of pain signals.

Read more
Add your reaction Share

Effects of anandamide in migraine: data from an animal model

Effects of anandamide in migraine: data from an animal model

Systemic nitroglycerin (NTG) produces spontaneous-like migraine attacks in migraine sufferers and induces a condition of hyperalgesia in the rat 4 h after its administration.

Read more
Add your reaction Share

Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?

Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? 

OBJECTIVES:

This study examines the concept of clinical endocannabinoid deficiency (CECD), and the prospect that it could underlie the pathophysiology of migraine, fibromyalgia, irritable bowel syndrome, and other functional conditions alleviated by clinical cannabis.

Read more
Add your reaction Share

EHMTI-0136. Medical cannabis in the treatment of treatment-resistant, chronic cluster headache

EHMTI-0136. Medical cannabis in the treatment of treatment-resistant, chronic cluster headache. A retrospective report

Cannabis was found an effective treatment for resistant chronic cluster-headache, with minimal adverse-events.

http://www.thejournalofheadacheandpain.com/content/15/S1/C46 

(The Journal of Headache and Pain 2014, 15(Suppl 1):C46)

Read more
Add your reaction Share